Showing 1 - 8 results of 8 for search 'Michelle Xia', query time: 0.03s Refine Results
  1. 1
    Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

    Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity by Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia, Baiyong Li

    Published 2023-12-01
    Get full text
    Article
  2. 2
    1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects

    1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative bio... by Baiyong Li, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Xinrong He, Jose Montoya, Betty Chang, Michelle Xia, Jing Min

    Published 2023-11-01
    Article
  3. 3
    Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

    Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind,... by Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Benchao Chen, Max Wang, Baiyong Li, Michelle Xia, Rodney Sinclair

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects

    Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological... by Tingting Zhong, Lingzhi Zhang, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Wenrong Liu, Juan Du, Wen Yin, Na Chen, Jing Min, Michelle Xia, Baiyong Li

    Published 2025-03-01
    Get full text
    Article
  5. 5
    Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

    Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis by Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, Max Wang, Michelle Xia, Baiyong Li, Rui Chen, Pei Hu

    Published 2022-08-01
    Get full text
    Article
  6. 6
    Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

    Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab by Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo

    Published 2024-09-01
    Get full text
    Article
  7. 7
    The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

    The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical tri... by Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Aibing Xu, Meili Sun, Wei Wang, Jian Wu, Ming Huang, Lijie Song, Luke Huang, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Bai, Li Bai

    Published 2023-10-01
    Get full text
    Article
  8. 8
    AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialResearch in context

    AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II tr... by Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Qitao Yu, Wu Zhuang, Yanqiu Zhao, Ming Zhou, Weidong Zhang, Yu Zhang, Yixin Wan, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang

    Published 2023-08-01
    Get full text
    Article

Search Tools: